Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells

Journal of Immunology

Volumn 170, Issue 9, 2003, Pages 4483-4488

  Vieira, Pedro L ^a,b   Heystek, Heleen C ^a   Wormmeester, Jan ^a   Wierenga, Eddy A ^a   Kapsenberg, Martien L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; INHIBITION KINETICS; MODULATION; POLARIZATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH2 CELL;

EID: 0037406714     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.9.4483     Document Type: Article

References (53)

1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol. Today 17:138.
3. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275.
4. Kalinski, P., C. M. Hilkens, E. A. Wierenga, and M. L. Kapsenberg. 1999. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20:561.
5. Pulendran, B., J. Banchereau, E. Maraskovsky, and C. Maliszewski. 2001. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22:41.
6. Hilkens, C. M., P. Kalinski, M. de Boer, and M. L. Kapsenberg. 1997. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90:1920.
7. Verhasselt, V., C. Buelens, F. Willems, D. De Groote, N. Haeffner-Cavaillon, and M. Goldman. 1997. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J. Immunol. 158:2919.
8. Sparwasser, T., E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, and H. Wagner. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:2045.
9. Snijders, A., P. Kalinski, C. M. Hilkens, and M. L. Kapsenberg. 1998. High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. 10:1593.
10. Cella, M., M. Salio, Y. Sakakibara, H. Langen, I. Julkunen, and A, Lanzavecchia. 1999. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189:821.
11. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
12. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741.
13. + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161:2804.
14. Mazzoni, A., H. A. Young, J. H. Spitzer, A. Visintin, and D. M. Segal. 2001: Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J. Clin. Invest. 108:1865.
15. Caron, G., Y. Delneste, E. Roelandts, C. Duez, J.-Y. Bonnefoy, J. Pestel, and P. Jeannin. 2001. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J. Immunol. 167:3682.
16. + T cells to secrete IL-4. Int. Immunol. 10:1017.
17. De Smedt, T., M. Van Mechelen, G. De Becker, J. Urbain, O. Leo, and M. Moser. 1997. Effect of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. 27:1229.
18. Vanderheyde, N., V. Verhasselt, M. Goldman, and F. Willems. 1999. Inhibition of human dendritic cell functions by methylprednisolone. Transplantation 67:1342.
19. Panina-Bordignon, P., D. Mazzeo, P. D. Lucia, D. D'Ambrosio, R. Lang, L. Fabbri, C. Self, and F. Sinigaglia. 1997. β2-agonists prevent Th1 development by selective inhibition of interleukin 12. J. Clin. Invest. 100:1513.
20. Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon, and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:242.
21. Teitelbaum, D., M. Fridkis-Hareli, R. Arnon, and M. Sela. 1996. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:209.
22. Ben-Nun, A., I. Mendel, R. Bakimer, M. Fridkis-Hareli, D. Teitelbaum, R. Arnon, M. Sela, and N. Kerlero de Rosbo. 1996. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. 243:S14.
23. Fridkis-Hareli, M., E. F. Rosloniec, L. Fugger, and J. L. Strominger. 1998. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type 11 collagen-reactive T cell clones. Proc. Natl. Acad. Sci. USA 95:12528.
24. Schlegel, P. G., R. Aharoni, Y. Chen, J. Chen, D. Teitelbaum, R. Arnon, M. Sela, and N. J. Chao. 1996. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc. Natl. Acad. Sci. USA 93:5061.
25. Aharoni, R., P. G. Schlegel, D. Teitelbaum, O. Roikhel-Karpov, Y. Chen, R. Arnon, M. Sela, and N. J. Chao. 1997. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol. Lett. 58:79.
26. Aharoni, R., D. Teitelbaum, R. Arnon, and M. Sela. 2001. Copolymer 1 inhibits manifestations of graft rejection. Transplantation 72:598.
27. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, and R. B. Schiffer. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268.
28. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, R. B. Schiffer, et al. 1998. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer 1 Multiple Sclerosis Study Group. Neurology 50:701.
29. Mancardi, G. L., F. Sardanelli, R. C. Parodi, E. Melani, E. Capello, and M. Inglese. 1998. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 50:1127.
30. Johnson, K. P., B. R. Brooks, C. C. Ford, A. Goodman, J. Guarnaccia, R. P. Lisak, L. W. Myers, H. S. Panitch, A. Pruitt, J. W. Rose, et al. 2000. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years: Copolymer 1 Multiple Sclerosis Study Group. Mult. Scler. 6:255.
31. Neuhaus, O., C. Farina, H. Wekerle, and R. Hohlfeld. 2001. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702.
32. Fridkis-Hareli, M., D. Teitelbaum, E. Gurevich, I. Pecht, C. Brautbar, O. J. Kwon, T. Brenner, R. Arnon, and M. Sela. 1994. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc. Natl. Acad. Sci. USA 91:4872.
33. Fridkis-Hareli, M., and J. L. Strominger. 1998. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J. Immunol. 160:4386.
34. Aharoni, R., D. Teitelbaum, M. Sela, and R. Arnon. 1998. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J. Neuroimmunol. 91:-135.
35. Teitelbaum, D., R. Aharoni, R. Arnon, and M. Sela. 1988. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc. Natl. Acad. Sci. USA 85:9724.
36. Teitelbaum, D., R. Milo, R. Arnon, and M. Sela. 1992. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc. Natl. Acad. Sci. USA 89:137.
37. Aharoni, R., D. Teitelbaum, R. Arnon, and M. Sela. 1999. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. USA 96:634.
38. Aharoni, R., D. Teitelbaum, M. Sela, and R. Arnon. 1997. Copolymer 1 induces T cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 94:10821.
39. Aharoni, R., D. Teitelbaum, O. Leitner, A. Meshorer, M. Sela, and R. Arnon. 2000. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. USA 97:11472.
40. Dabbert, D., S. Rosner, M. Kramer, U. Scholl, H. Tumani, M. Mader, and F. Weber. 2000. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci. Lett. 289:205.
41. Duda, P. W., M. C. Schmied, S. L. Cook, J. I. Krieger, and D. A. Hafler. 2000. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105:967.
42. Gran, B., L. R. Tranquill, M. Chen, B. Bielekova, W. Zhou, S. Dhib-Jalbut, and R. Martin. 2000. Mechanisms of immunomodulation by glatiramer acetate. Neurology 55:1704
43. Miller, A., S. Shapiro, R. Gershtein, A. Kinarty, H. Rawashdeh, S. Honigman, and N. Lahat. 1998. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 92:113.
44. Neuhaus, O., C. Farina, A. Yassouridis, H. Wiendl, B. F. Then, T. Dose, H. Wekerle, and R. Hohlfeld. 2000. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. USA 97:7452.
45. Lobel, E., R. Riven-Kreitman, A. Amselem, and I. Pinchasi. 1996. Copolymer-1 Drugs Future. 21:131.
46. Weiner, H. L. 1999. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. USA 96:3333.
47. Windhagen, A., S. Maniak, S. Marckmann, R. B. Lindert, F. Heidenreich, and R. Blasczyk. 2001. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate. J. Neurol. Nearosurg. Psychiatry 70:415.
48. Wiesemann, E., J. Klatt, D. Sonmez, R. Blasczyk, F. Heidenreich, and A. Windhagen. 2001. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J. Neuroimmunol. 119:137.
49. Hussien, Y., A. Sanna, M. Soderstrom, H. Link, and Y. M. Huang. 2001. Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis. J. Neuroimmunol. 121:102.
50. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immun. 3:135.
51. Li, Q. Q., and C. T. Bever. 2001. Glatiramer acetate blocks interleukin-1-dependent nuclear factor-κB activation and RANTES expression in human U-251 MG astroglial cells. Brain Res. Mol. Brain Res. 87:48.
52. tk;Rescigno, M., M. Martino, C. L. Sutherland, M. R. Gold, and P, Ricciardi-Castagnoli, 1998. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188:2175.
53. Baldwin, A. S., Jr. 1996. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649.